SRGA Surgalign Holdings Inc

Surgalign Schedules Second Quarter 2022 Earnings Release for August 9, 2022

Surgalign Schedules Second Quarter 2022 Earnings Release for August 9, 2022

DEERFIELD, Ill., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced its plans to release financial results for its second quarter ended June 30, 2022 after the close of trading on August 9, 2022.

Surgalign will host a conference call and audio webcast at 4:30 p.m. ET the same day. The conference call can be accessed by dialing (888) 645-4404 (U.S.) or (404) 267-0371 (International). The webcast can be accessed through the investor section of Surgalign’s website at . A replay of the conference call will be available on Surgalign’s website for one month following the call.

About Surgalign Holdings, Inc.

Surgalign Holdings, Inc. is a global medical technology company committed to the promise of digital health to drive transformation across the surgical landscape. Uniquely aligned and resourced to advance the standard of care, the company is building technologies physicians and other health providers will look to for what is truly possible for their patients. Surgalign is focused on developing solutions that predictably deliver superior clinical and economic outcomes. Surgalign markets products throughout the United States and in approximately 50 countries worldwide through an expanding network of top independent distributors. Surgalign is headquartered in Deerfield, IL, with commercial, innovation and design centers in San Diego, CA, Warsaw and Poznan, Poland, and Wurmlingen, Germany. Learn more at and connect on LinkedIn and Twitter.

Forward Looking Statement

This press release contains forward-looking statements based on management’s current expectations, estimates and projections about our products, company, and industry, our management's beliefs, and certain assumptions made by our management. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and other variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in our public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company's SEC filings may be obtained by contacting the company or the SEC or by visiting Surgalign's website at or the SEC’s website at .

Investor and Media Contact:Surgalign Contact:
Glenn Wiener Kristine Simmons
  



EN
01/08/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Surgalign Holdings Inc

 PRESS RELEASE

Surgalign Receives NASDAQ Delisting Notice Following its Chapter 11 Fi...

Surgalign Receives NASDAQ Delisting Notice Following its Chapter 11 Filing Delisting to take effect on July 3, 2023; Company’s common stock is expected to begin trading on the OTC under the symbol SRGAQ DEERFIELD, Ill., June 23, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, announced today that on June 22, 2023, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”). Nasdaq has determined that du...

 PRESS RELEASE

Surgalign Enters Into Definitive Agreement to Sell Global Hardware and...

Surgalign Enters Into Definitive Agreement to Sell Global Hardware and Biologics Business Through a Structured Sale Process Under Chapter 11 of the U.S. Bankruptcy Code DEERFIELD, Ill., June 20, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) (“Surgalign” or the “Company”) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced that the Company has entered into an asset purchase agreement (the “Asset Purchase Agreement”) to sell substantially all of its U.S. hardware and biomaterials assets...

 PRESS RELEASE

Surgalign to Participate at ISASS 2023 – 23rd Annual Conference Sponso...

Surgalign to Participate at ISASS 2023 – 23rd Annual Conference Sponsored by the International Society for the Advancement of Spine Surgery and Medical Education Resources Company to showcase its upgraded HOLO Portal™ Surgical Guidance System and key products in its hardware spine and biologics portfolio DEERFIELD, Ill., May 23, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, announced today that it will be exhibiting at ISASS 2023 – the 23rd Annual ...

 PRESS RELEASE

Surgalign Announces First Quarter 2023 Results and Provides Update on ...

Surgalign Announces First Quarter 2023 Results and Provides Update on its Business Operations DEERFIELD, Ill., May 11, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced financial results for its 2023 first quarter ended March 31, 2023. 2023 First Quarter and Subsequent Corporate Highlights: Launch of HOLO™ AI Insights for Spine Imaging; collaboration with Dr. Alexander Vaccaro, Dr. Pierce Nunley and Spine Institute of Louisiana, and l...

 PRESS RELEASE

Surgalign Announces Release of HOLO™ AI Insights for Neurovascular Res...

Surgalign Announces Release of HOLO™ AI Insights for Neurovascular Research New HOLO AI Insights application aims to advance research of neuroanatomy utilizing artificial intelligence DEERFIELD, Ill., May 08, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, is proud to announce today, the release of HOLO™ AI Insights for use in neurovascular research. HOLO AI Insights, initially launched in March 2023 for spine imaging, enables customers, partners, ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch